Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Mustang Bio Completes a $75 Million Debt Financing with Runway Growth Capital
-
Mustang Bio Completes a $75 Million Debt Financing with Runway Growth Capital
-
Iris Energy Limited Announces Monthly Investor Update for February 2022
-
Iris Energy Limited Announces Monthly Investor Update for February 2022
-
SatixFy to Go Public via Combination with Endurance Acquisition Corp. (EDNC)
-
SatixFy, a Leader in Next-Generation Satellite Communication Systems, to Go Public via Combination with Endurance Acquisition Corp.
-
Cantor Fitzgerald Reiterates Cidara Therapeutics (CDTX) at Overweight, Believes the Street Underappreciates Company's Sales Potential, Sees Upward Earnings Revisions
-
Alpha Tau Medical and Healthcare Capital Corp. Announce Completion of Business Combination
-
Brooklyn ImmunoTherapeutics Announces $12 Million Private Placement
-
Cantor Fitzgerald Reiterates TherapeuticsMD (TXMD) at Overweight, $5 PT, VitaCare Sale is Good News, Priced Above Expectation, Increases Confidence in the Stock
-
Cantor Fitzgerald Reiterates VYNE Therapeutics (VYNE) at Overweight, Newest Data Supports Positive Thesis for Stock
-
Atlantic Coastal Acquisition Corp. II Announces the Separate Trading of its Shares of Series A Common Stock and Warrants Commencing March 7, 2022
-
Cantor Fitzgerald Reiterates Overweight Rating on Evolus (EOLS), Jeuveau's Value Proposition is Underappreciated
-
Curaleaf (CURLF) PT Lowered to $15.50 at Cantor Fitzgerald
-
Hexo Corp. (HEXO:CN) (HEXO) PT Lowered to Cdn$0.90 at Cantor Fitzgerald
-
Cantor Fitzgerald Reiterates Hutchison China MediTech Ltd. (HCM) at Overweight, Believes HCM's Pipeline is Underappreciated
-
Cantor Fitzgerald Reiterates EyePoint (EYPT) at Overweight, Believes Potential Peak Sales for EYP-1901 Remains Underappreciated
-
Cantor Fitzgerald Reiterates Entasis Therapeutics (ETTX) at Overweight, Believes More Value to Unlocked in Shares
-
Form 8-K Cantor Fitzgerald Income For: Mar 01
-
McEwen Mining Closes Flow-Through Financing
-
McEwen Mining Closes Flow-Through Financing
-
Cantor Fitzgerald Reiterates Avalo (AVTX) at Overweight, Peak Sales Potential of Pipeline is Underappreciated
-
Graphite Corp. (GRPH) Appoints Alethia Young as Chief Financial Officer
-
Graphite Bio Appoints Alethia Young as Chief Financial Officer
-
10X Capital Venture Acquisition Corp. III Announces the Separate Trading of its Ordinary Shares and Warrants, Commencing March 4, 2022
-
10X Capital Venture Acquisition Corp. III Announces the Separate Trading of its Ordinary Shares and Warrants, Commencing March 4, 2022
-
Form X-17A-5 CANTOR FITZGERALD & CO. For: Dec 31
-
Amryt (AMYT) PT Lowered to $25 at Cantor Fitzgerald
-
Cantor Fitzgerald Reiterates Amarin Corporation (AMRN) at Overweight, "Street is Underestimating Multi-billion Dollar Opportunity for Vascepa/Vazkepa"
-
Novavax (NVAX) Stock Falls 6% on Weak Sales Guidance, Analyst Remains Positive
-
Heron Therapeutics (HRTX) PT Lowered to $20 at Cantor Fitzgerald
-
Cantor Fitzgerald Reiterates Johnson & Johnson (JNJ) at Overweight, Pharm Business is Underappreciated, Expect Upwards Earnings Revisions and Multiple Expansion
-
Cantor Fitzgerald Reiterates Ardelyx (ARDX) at Overweight, Peak Sales Potential of Pipeline is Underappreciated
-
Cantor Fitzgerald Reiterates Overweight Rating on Humanigen (HGEN), Expects Upward Earnings Revisions
-
C5 Acquisition Corporation Announces the Separate Trading of its Class A Common Stock and Warrants, Commencing February 28, 2022
-
Cantor Fitzgerald Starts Journey Medical Corp. (DERM) at Overweight
-
Katapult Holdings (KPLT) PT Lowered to $4 at Cantor Fitzgerald
-
Delwinds Insurance Acquisition Corp. (DWIN) and FOXO Technologies Announce Merger Agreement
-
FOXO Technologies Inc. Enters Into Business Combination Agreement with Delwinds Insurance Acquisition Corp.
-
FOXO Technologies Inc. Enters Into Business Combination Agreement with Delwinds Insurance Acquisition Corp.
-
Orchid Island Capital Announces Fourth Quarter 2021 Results
-
Cantor Fitzgerald Reiterates Aclaris Therapeutis (ACRS) at Overweight, "Still a Lot of Value to be Unlocked in ACRS's Pipeline"
-
Troika Media (TRKA) Acquires Converge Direct for $125M
-
Troika Media Group to Acquire Converge Direct LLC, a Leading Digital and Offline Performance Media and Marketing Company, for $125 Million
-
Troika Media Group to Acquire Converge Direct LLC, a Leading Digital and Offline Performance Media and Marketing Company, for $125 Million
-
Troika Media Group to Acquire Converge Direct LLC, a Leading Digital and Offline Performance Media and Marketing Company, for $125 Million
-
Cantor Fitzgerald Reiterates Overweight Rating on Vaxcyte (PCVX), VAX-24 Study Patient Dosing Brings the Company Closer to Potential Commercialization
-
William Ferri Joins Cantor Fitzgerald to Lead Expansion of Asset Management Platform
-
UPDATE: Cantor Fitzgerald Starts Affimed Therapeutics (AFMD) at Overweight
-
Arcutis (ARQT) Reiterated at Overweight by Cantor Fitzgerald, Company's Opportunity to Become Medical Dermatology Leader Remains Underappreciated

